November 30, 2025
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”)
Injuries are part of living. Scrapes, fractures, and scar healing remind us that the body can repair itself. However, some wounds go deeper, beyond what nature and conventional treatments can do. For instance, when you have an injury in complex or protected areas of the body like the brain and